Announcements - QBiotics

Company Announcements

Date

Title

QBiotics lodges Prospectus to support its next phase of growth

QBiotics reports 78% overall response rate in injected tumours treated with tigilanol tiglate in a Phase II head and neck cancer clinical trial

QBiotics EBC-1013 wound healing trial advances to fourth cohort

June 2026 Shareholder Update

QBiotics to present at BIO 2026 International Convention and participate in MTEC Annual Meeting

QBiotics appoints Geoff Miller as Non-executive Director

QBiotics to participate in the first international symposium dedicated to intratumoural immunotherapy

QBiotics appoints Andrew Craig to the role of Global Investor Relations Officer

March 2026 Shareholder Update

QBiotics Group 2026-2027 Strategic Plan Overview

31 December 2025 Interim Financial Report

QBiotics and Unicancer France sign letter of intent to collaborate on a clinical Phase II Trial, targeting breast cancer recurrence

Update on STELFONTA® Supply and Distribution Arrangements

QBiotics receives $7.7M tax incentive refund

QBiotics CFO and Company Secretary update

QBiotics Board and Executive update

QBiotics CEO and board update

CEO's 2025 AGM presentation and Results of the Meeting

QBiotics 2025 AGM Chair key remarks

QBiotics further clarifies recent leadership changes and provides context on AGM voting

2025 Annual General Meeting

QBiotics leadership update

David Phillips appointed Deputy Chair

First three patients dosed in Stage 2 of Phase IIa clinical trial of tigilanol tiglate in Soft Tissue Sarcoma

2025 Annual Report

First cohort successfully dosed in EBC-1013 Phase I wound healing clinical trial

QBiotics appoints Sergio Duchini as Non-executive Director

QBiotics reports 80% objective response rate in injected tumours in Stage 1 of Phase IIa clinical trial of tigilanol tiglate for Soft Tissue Sarcoma

May 2025 Shareholder Update

QBiotics appoints Jefferies and Bell Potter as Joint Lead Managers

Non-executive Director resignation

February 2025 Shareholder Update

QBiotics data presented at Society of Surgical Oncology Advanced Cancer Therapies 2025 Annual Meeting

31 December 2024 Interim Financial Report

STELFONTA® label extended in Great Britain

QBiotics strengthens medical leadership with appointment of CMO and world leading oncologist consultant

QBiotics receives $7.38m R&D tax incentive refund

2024 Annual General Meeting - CEO Presentation and Results of the Meeting

Bell Potter Healthcare Conference presentation

QBiotics Phase IIa Soft Tissue Sarcoma trial extended, following positive data presented at CTOS

QBiotics board changes

Mark Fladrich appointed Chair of QBiotics

Vale Dr Susan Foden, Non-executive Chair

QBiotics leadership transition

2024 Annual General Meeting

Preliminary data from QBiotics’ Phase IIa clinical trial in Soft Tissue Sarcoma presented at ESMO Congress 2024

QBiotics appoints world class Clinical Advisory Board

2024 Annual Report

August 2024 Shareholder Update

QBiotics welcomes Stephen Doyle as Chief Executive Officer

QBiotics Phase IIa clinical trial in Soft Tissue Sarcoma completion of patient recruitment

QBiotics receives $8.63m R&D tax incentive refund

May 2024 Shareholder Update

QBiotics to present at the 10th Annual Sachs Oncology Innovation Forum 2024 and BIO International Convention 2024

Board appointments at QBiotics Group

Tigilanol tiglate preclinical data published in Journal for ImmunoTherapy of Cancer

31 December 2023 Interim Financial Report

February 2024 Shareholder Update

QBiotics drug tigilanol tiglate awarded Orphan Drug Designation for patients with soft tissue sarcoma

Annual General Meeting Shareholder Presentation 2023

Board and Executive changes at QBiotics Group

New STELFONTA® data presented at the 2023 Veterinary Cancer Society Annual Conference

QBiotics to present advances from its oncology and wound healing programmes at key conferences in October and November

2023 Annual Report

August 2023 Shareholder Update

QBiotics’ tigilanol tiglate meets Primary Endpoints in its Phase I/IIa head and neck cancer dose escalation trial

First patient treated in QBiotics' Phase II clinical trial in patients with soft tissue sarcoma

BIO International Convention presentation

Sachs 9th Annual Immuno-Oncology Innovation Forum presentation

QBiotics to present at Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention

Changes to the Board of Directors

May 2023 Shareholder Update

QBiotics opens Phase II clinical trial to investigate the preliminary efficacy of Tigilanol Tiglate in soft tissue sarcoma

First patient treated in QBiotics’ Phase II Clinical Trial treating head and neck cancer with tigilanol tiglate

31 December 2022 Interim Financial Report

QBiotics announces amended human clinical strategy for tigilanol tiglate and Non-executive Director resignation

QBiotics Poster Presentation at SITC 2022

Update of QBiotics Group human oncology clinical trials

QBiotics appoints new Chair and Deputy Chair

Resignation of non-executive chair

Annual General Meeting CEO Presentation 2022

30 June 2022 Annual Report

FDA approves IND to initiate soft tissue sarcoma (STS) trial

COVID-19 impact update

31 December 2021 Interim Financial Report

Phase I/II trial (QBC46-H03) completes recruitment

STELFONTA® launches in Australia

APVMA approves registration of STELFONTA

QBiotics concludes successful $85 million capital raise

First patient dosed in QBiotics and MSD clinical trial collaboration for unresectable melanoma

Prospectus – Offer opens and Application Forms now available

QBiotics lodges Prospectus in preparation for share offer to Existing Shareholders

QBiotics raises AU$22.55 million from existing Sophisticated Investors

Hamish Corlett joins the Board of QBiotics

QBiotics announces plan to increase capital raise to up to AU$85 million

Cornerstone Investor Joins QBiotics

QBiotics announces plan to raise up to AU$75 million

QBiotics welcomes TDM Growth Partners as cornerstone investor

QBiotics’ first USA shipment of STELFONTA®

Nicholas Moore joins the Board of QBiotics

FDA approves registration of STELFONTA^®

STELFONTA^® USA Marketing Authorisation Progress

QBiotics announces clinical collaboration with MSD targeting unresectable melanoma

QBiotics doses first Australian patient in Phase I/II clinical trial for head and neck cancer

Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA^® (tigilanol tiglate) removes 75% of tumours

QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA^®

QBiotics raises AU$17.76 million from Sophisticated Investors

QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA^®

The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal

QBiotics announces first patient dosed in its Phase I/II clinical trial of tigilanol tiglate for head and neck cancer

STELFONTA Progress with European Medicines Authority

Dr Susan Foden joined the Board of QBiotics

Scientific Presentations: Veterinary Cancer Society, Houston, USA

Tigilanol tiglate canine mast cell tumour (MCT) pivotal field efficacy clinical trial results presented at prestigious international congresses

International Publication - Tigilanol Tiglate Canine Dose Characterisation Study